SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Englund J. Diagnosis and epidemiology of community-acquired respiratory virus infections in the immunocompromised host. Biol Blood Marrow Transplant. 2001; 7 Suppl: 2S4S.
  • 2
    Whimbey E, Bodey GP. Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of the common community respiratory viruses. Semin Respir Infect. 1992; 7: 122131.
  • 3
    Englund JA, Sullivan CJ, Jordan MC. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 1988; 109: 203208.
  • 4
    Couch RB, Englund JA, Whimbey E. Respiratory viral infection in immunocompetent and immunocompromised persons. Am J Med. 1997; 102: 29.
  • 5
    Kantrow SP, Hackman RC, Boeckh M, et al. Idiopathic pneumonia syndrome. Transplantation. 1997; 63: 10791086.
  • 6
    Hall CB. Medical progress: respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001; 344: 19171928.
  • 7
    Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 1997; 102: 1024.
  • 8
    Ljungman P, Gleaves CA, Meyers JD. Respiratory virus infections in immunocompromised patients. Bone Marrow Transplant. 1989; 4: 3540.
  • 9
    Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992; 326: 921926.
  • 10
    Henrickson KJ, Kuhn SM, Savatski LL. Epidemiology and cost of infection with human parainfluenza virus types 1 and 2 in young children. Clin Infect Dis. 1994; 18: 770779.
  • 11
    Ressel GW. ACIP releases 2002 guidelines on the prevention and control of influenza. Advisory Committee on Immunization Practices. Am Fam Physician. 2002; 66: 894, 899, 900.
  • 12
    Oates JA, Wood AJ. Prophylaxis and treatment of influenza. N Engl J Med. 1990; 322: 443449.
  • 13
    Douglas RG Jr., Hall WJ, Betts RF. Changing virulence of influenza A viruses. Trans Am Clin Climat Assoc. 1981; 112: 814819.
  • 14
    Glezen WP, Greenberg SB, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000; 283: 499505.
  • 15
    Ljungman P. Respiratory virus infections in stem cell transplant patients: The European experience. Biol Blood Marrow Transplant. 2001; 7 Suppl: 5S7S.
  • 16
    Bowden RA. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience. Am J Med. 1997; 102: 2730.
  • 17
    Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996; 22: 778782.
  • 18
    Murphy BR, Webster RG. Orthomyxoviruses. In: FieldsBN, KnipeDM, ChanockRM, et al., editors. Virology, 2nd edition. New York: Raven, 1990: 10911152.
  • 19
    Kilbourne ED. Influenza. New York: Plenum, 1987.
  • 20
    Palese P, Young JF. Variations of influenza A, B, and C viruses. Science. 1982; 215: 14681474.
  • 21
    Update: respiratory syncytial virus activity—United States, 1997–1998 season. MMWR Morb Mortal Wkly Rep. 1997; 46: 11631165.
  • 22
    Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis. 1990; 162: 12831290.
  • 23
    Peret TC, Hall CB, Schnabel KC, et al. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol. 1998; 79: 22212229.
  • 24
    Lindquist SW, Darnule A, Istra A, Demmler GJ. Parainfluenza virus type 4 infections in pediatric patients. Pediatr Infect Dis J. 1997; 16: 3438.
  • 25
    Englund JA, Whimbey E, Atmar RL. Diagnosis of respiratory viruses in cancer and transplant patients. In: RemingtonJS, SwartzMN, editors. Current clinical topics in infectious diseases. Malden, MA: Blackwell Science, 1999: 3059.
  • 26
    Wright PF, Thompson J, Karzon DT. Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol. 1980; 112: 814819.
  • 27
    Wohl ME, Chernick V. Bronchiolitis. Am Rev Respir Dis. 1978; 118: 759781.
  • 28
    Whimbey E, Ghosh S. Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis. 2000; 20: 232255.
  • 29
    Wendt CH, Hertz MI. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect. 1995; 10: 224231.
  • 30
    Sable CA, Hayden FG. Orthomyxoviral and paramyxoviral infections in transplant patients. Infect Dis Clin North Am. 1995; 9: 9871003.
  • 31
    Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 1992; 165: 987993.
  • 32
    Small TN, Casso A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002; 29: 321327.
  • 33
    Long CE, McBride JT, Hall CB. Sequelae of respiratory syncytial virus infections: a role for intervention studies. Am J Respir Crit Care Med. 1995; 151: 16781681.
  • 34
    Treanor JJ. Influenza virus. In: MandellGL, BennettJE, DolinR, editors. Principles and practice of infectious diseases, 4th edition. New York: Churchill Livingstone, 1995.
  • 35
    Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994; 13: 437440.
  • 36
    Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996; 23: 10331037.
  • 37
    Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med. 1997; 102: 4852.
  • 38
    Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant. 2001; 7 Suppl: 19S22S.
  • 39
    Englund JA, Piedra PA, Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 1997; 102: 6170.
  • 40
    Champlin RE, Whimbey E. Community respiratory virus infections in bone marrow transplant recipients: The M. D. Anderson Cancer Center experience. Biol Blood Marrow Transplant. 2001; 7 Suppl: 8S10S.
  • 41
    Dowell SF, Anderson LJ, Gary HE Jr., et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. 1996; 174: 456462.
  • 42
    Couch RB, Englund JA, Whimbey E. Respiratory virus infections in immunocompetent and immunocompromised persons. Am J Med. 1997; 102: 29.
  • 43
    Wingard JR. Viral infections in leukemia and bone marrow transplant patients. Leuk Lymphoma. 1993; 11: 115125.
  • 44
    Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med. 1986; 315: 7781.
  • 45
    Whimbey E, Couch RB, Englund JA, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 1995; 21: 376379.
  • 46
    Fan J, Henrickson KJ, Savatski LL. Rapid simultaneous diagnosis of infections with RSV viruses A and B, influenza A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription–polymerase chain reaction–enzyme hybridization assay (Hexaplex). Clin Infect Dis. 1998; 26: 13971402.
  • 47
    Falsey AR, McCann RM, Hall W, Criddle MM. Evaluation of four methods for the diagnosis of RSV infections in immunocompromised adults. J Am Geriatr Soc. 1996; 44: 7174.
  • 48
    Falsey AR, McCann RM, Hall WJ, et al. Respiratory syncytial virus infection in daycare centers for older persons. J Am Geriatr Soc. 1995; 43: 3036.
  • 49
    Mahmood W, Sacks S. Anti-infective therapy for viral pneumonia. Semin Respir Infect. 1995; 10: 270281.
  • 50
    Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med. 1997; 102: 5560.
  • 51
    PeterG, editor. Report of the Committee on Infectious Disease: 1994 red book, 23rd edition. Elk Grove Village, IL: American Academy of Pediatrics, 1994: 275283.
  • 52
    Centers for Disease Control. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR. 1992; 41: 117.
  • 53
    Gross PA, Gould AL, Brown AE. Effect of cancer chemotherapy on the immune response to influenza vaccine. Review of published studies. Rev Infect Dis. 1985; 7: 613618.
  • 54
    Van Voris LP, Newell PM. Antivirals for the chemoprophylaxis and treatment of influenza. Semin Respir Infect. 1992; 7: 6170.
  • 55
    Hayden FG. Amantadine and rimantadine—clinical aspects. In: RichmanDR, editor. Antiviral drug resistance. Chichester: John Wiley and Sons, Ltd., 1996: 5977.
  • 56
    Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother. 1999; 44: 2329.
  • 57
    Luo M, Air GM, Brouilette WJ. Design of aromatic inhibitors of influenza virus neuraminidase. J Infect Dis. 1997; 176 Suppl 1: S6265.
  • 58
    Nicholson KG, Aoki FY, Osterhaus ME, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet. 2000; 355: 18451850.
  • 59
    Sparrelid E, Ljungman P, Andersson J, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997; 19: 905908.
  • 60
    Gilbert BE, Wilson SZ, Knight V, et al. Ribavirin small particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83(H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985; 27: 309313.
  • 61
    Knight V, Wilson SZ, Quarles JM, et al. Ribavirin small particle aerosol treatment of influenza. Lancet. 1981; 2: 945949.
  • 62
    McClung HW, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of influenza B infection. JAMA. 1983; 249: 26712674.
  • 63
    Wilson SZ, Gilbert BE, Quarles JM, et al. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984; 26: 200203.
  • 64
    Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Res. 1996; 29: 4558.
  • 65
    McIntosh K, Kurachek SC, Goodspeed B. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. Am J Dis Child. 1984; 138: 305308.
  • 66
    Nichols WG, Corey L, Gooley T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001; 98: 573578.
  • 67
    Wendt CH, Weisdorf DR, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992; 326: 921926.
  • 68
    Nichols WG, Gooley T, Boeckh M. Community acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001; 7 Suppl: 11S15S.
  • 69
    Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995; 16: 393399.
  • 70
    Division of Health Promotion and Disease Prevention, Division of International Health, Institute of Medicine (IOM) Committee on Issues and Priorities for New Vaccine Development. New vaccine development: establishing priorities; volume II. Diseases of importance in developing countries. Washington, DC: National Academies Press, 1986: 299308.
  • 71
    Kim HW, Canchola JG, Brand CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89: 422434.
  • 72
    Robinson RF, Nahata MC. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Am J Health Syst Pharm. 2000; 57: 259267.
  • 73
    PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 1997; 99: 9399.
  • 74
    Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993; 329: 15241530.
  • 75
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998; 102; 12111216.
  • 76
    The Impact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalizations from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998; 102: 531537.
  • 77
    Welliver RC. Immunologic mechanisms of virus-induced wheezing and asthma. J Pediatr. 1999; 135: 1420.
  • 78
    Carubelli CM, Jafri HS, Sanchez PJ, et al. Ribavirin suppresses pro-inflammatory cytokine production in pulmonary epithelial cells infected with respiratory syncytial virus [abstract]. Pediatr Res. 1999; 45: 158A.
  • 79
    Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999; 354: 527528.
  • 80
    Edell D, Khoshoo V, Ross G, Salter K. Early ribavirin treatment of bronchiolitis. Chest. 2002; 122: 935939.
  • 81
    Sheeran P, Jafri H, Carubelli C, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis. 1999; 18: 115122.
  • 82
    Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 1991; 325: 2429.
  • 83
    Randolph AG, Wang EL. Ribavirin for respiratory syncytial virus lower respiratory tract infection. Arch Pediatr Adolesc Med. 1996; 150: 942947.
  • 84
    Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immune globulin. Bone Marrow Transplant. 2000; 25: 751755.
  • 85
    Adams RH, Christenson JC, Peterson FB, Beatty PG. Pre-emptive use of aerosolized ribavirin in the treatment of asymptomatic pediatric marrow transplant recipients testing positive for RSV. Bone Marrow Transplant. 1999; 24: 661664.
  • 86
    Englund JA, Piedra PA, Ahn Y, et al. High-dose, short duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1994; 125: 635641.
  • 87
    McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection and adult BMT recipients: effective therapy with short duration nebulized ribavirin. Bone Marrow Transplant. 1998; 21: 424425.
  • 88
    DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transplant. 2000; 25: 161165.
  • 89
    DeVincenzo JP, Leombruno D, Soiffer RJ, Siber GR. Immunotherapy of respiratory syncytial virus following bone marrow transplantation. Bone Marrow Transplant. 1996; 17: 10511056.
  • 90
    Boeckh M, Berrey M, Bowden R, et al. Phase I evaluation of the respiratory syncytial virus–specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001; 184: 350354.